Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H, Uemura H, Nagamori S, Wakumoto Y, Kimura G, Kikukawa H, Yokomizo A, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Akagawa T, Matsubara N.
Uemura H, et al. Among authors: yonese j.
Int J Clin Oncol. 2019 May;24(5):557-566. doi: 10.1007/s10147-018-01389-4. Epub 2019 Mar 14.
Int J Clin Oncol. 2019.
PMID: 30875000
Free PMC article.
Clinical Trial.